Home > Oncology > ASCO 2019 > Breast Cancer > Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer

Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer

Presented By
Dr Ian E. Krop, Dana-Farber Cancer Institute, USA
Conference
ASCO 2019
Trial
Phase 3, APHINITY
Medical writer: Leah Lawrence A comprehensive genomic analysis of women with HER2-positive breast cancer enrolled in the APHINITY trial revealed several markers that may be associated with better prognosis and increased benefit from treatment with trastuzumab and pertuzumab (Abstract 1012). Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute, presented results of the analysis, which included DNA sequencing, RNA sequencing, tumour-infiltrating lymphocyte (TIL) analysis, and HER2 immunohistochemistry and FISH, during the “Targeting Breast Cancer: Breaking the Code” Clinical Science Symposium held June 1. APHINITY was a phase III study investigating the benefit of adjuvant therapy with pertuzumab when added to trastuzumab and chemotherapy in women with HER2-positive early-stage breast cancer. The trial demonstrated an invasive disease-free survival benefit to adding pertuzumab, but the overall magnitude was relatively small at only 1.7% difference...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on